Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2016 (2016), Article ID 4650471, 7 pages
http://dx.doi.org/10.1155/2016/4650471
Research Article

Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program: A Prospective Study

1St. Paul’s Hospital, Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
2British Columbia Cancer Agency, Vancouver, BC, Canada

Received 18 August 2016; Revised 6 November 2016; Accepted 9 November 2016

Academic Editor: Geoffrey Williams

Copyright © 2016 Neal Shahidi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Kronborg, C. Fenger, J. Olsen, O. D. Jørgensen, and O. Søndergaard, “Randomised study of screening for colorectal cancer with faecal-occult-blood test,” The Lancet, vol. 348, no. 9040, pp. 1467–1471, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. J. D. Hardcastle, J. O. Chamberlain, M. H. E. Robinson et al., “Randomised controlled trial of faecal-occult-blood screening for colorectal cancer,” The Lancet, vol. 348, no. 9040, pp. 1472–1477, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. J. S. Mandel, T. R. Church, J. H. Bond et al., “The effect of fecal occult-blood screening on the incidence of colorectal cancer,” The New England Journal of Medicine, vol. 343, no. 22, pp. 1603–1607, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. O. D. Jörgensen, O. Kronborg, and C. Fenger, “A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds,” Gut, vol. 50, no. 1, pp. 29–32, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Faivre, V. Dancourt, C. Lejeune et al., “Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study,” Gastroenterology, vol. 126, no. 7, pp. 1674–1680, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. W. S. Atkin, R. Edwards, I. Kralj-Hans et al., “Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial,” The Lancet, vol. 375, no. 9726, pp. 1624–1633, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Segnan, P. Armaroli, L. Bonelli et al., “Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial—SCORE,” Journal of the National Cancer Institute, vol. 103, no. 17, pp. 1310–1322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. R. E. Schoen, P. F. Pinsky, J. L. Weissfeld et al., “Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy,” The New England Journal of Medicine, vol. 366, no. 25, pp. 2345–2357, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Shaukat, S. J. Mongin, M. S. Geisser et al., “Long-term mortality after screening for colorectal cancer,” The New England Journal of Medicine, vol. 369, no. 12, pp. 1106–1114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. M. M. Center, A. Jemal, R. A. Smith, and E. Ward, “Worldwide variations in colorectal cancer,” CA: A Cancer Journal for Clinicians, vol. 59, no. 6, pp. 366–378, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Leddin, R. Enns, R. Hilsden et al., “Canadian Association of Gastroenterology position statement on screening individuals at average risk for developing colorectal cancer: 2010,” Canadian Journal of Gastroenterology, vol. 24, no. 12, pp. 705–714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. U.S. Preventive Services Task Force, “Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement,” Annals of Internal Medicine, vol. 149, no. 9, pp. 627–637, 2008. View at Publisher · View at Google Scholar
  15. O. G. Dominic, T. McGarrity, M. Dignan, and E. J. Lengerich, “American College of Gastroenterology Guidelines for colorectal cancer screening 2008,” The American Journal of Gastroenterology, vol. 104, no. 10, pp. 2626–2627, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Levin, D. A. Lieberman, B. McFarland et al., “Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer and the American College of Radiology,” Gastroenterology, vol. 134, no. 5, pp. 1570–1595, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. Canadian Task Force on Preventive Health Care, “Recommendations on screening for colorectal cancer in primary care,” Canadian Medical Association Journal, vol. 188, no. 5, pp. 340–348, 2016. View at Publisher · View at Google Scholar
  18. J. E. Allison, C. G. Fraser, S. P. Halloran, and G. P. Young, “Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT),” Gut and Liver, vol. 8, no. 2, pp. 117–130, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. S. R. Cole and G. P. Young, “Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer,” Medical Journal of Australia, vol. 175, no. 4, pp. 195–198, 2001. View at Google Scholar · View at Scopus
  20. S. R. Cole, G. P. Young, A. Esterman, B. Cadd, and J. Morcom, “A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer,” Journal of Medical Screening, vol. 10, no. 3, pp. 117–122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Vart, R. Banzi, and S. Minozzi, “Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis,” Preventive Medicine, vol. 55, no. 2, pp. 87–92, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. H. E. Robinson, C. G. Marks, P. A. Farrands, W. M. Thomas, and J. D. Hardcastle, “Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests,” British Journal of Surgery, vol. 81, no. 3, pp. 448–451, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Rozen, J. Knaani, and N. Papo, “Evaluation and comparison of an immunochemical and a guaiac faecal occult blood screening test for colorectal neoplasia,” European Journal of Cancer Prevention, vol. 4, no. 6, pp. 475–481, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. J. E. Allison, I. S. Tekawa, L. J. Ransom, and A. L. Adrain, “A comparison of fecal occult-blood tests for colorectal-cancer screening,” The New England Journal of Medicine, vol. 334, no. 3, pp. 155–159, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. N. petrelli, A. M. Michalek, A. Freedman, M. Baroni, I. Mink, and M. Rodriguez-Bigas, “Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program,” Surgical Oncology, vol. 3, no. 1, pp. 27–36, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. D. I. Park, S. Ryu, Y.-H. Kim et al., “Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening,” The American Journal of Gastroenterology, vol. 105, no. 9, pp. 2017–2025, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. L. G. van Rossum, A. F. van Rijn, R. J. Laheij et al., “Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population,” Gastroenterology, vol. 135, no. 1, pp. 82–90, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. J. K. Lee, E. G. Liles, S. Bent, T. R. Levin, and D. A. Corley, “Accuracy of fecal immunochemical tests for colorectal cancer,” Annals of Internal Medicine, vol. 160, no. 3, pp. 171–181, 2014. View at Google Scholar · View at Scopus
  29. N. H. Kim, M. J. Kwon, H. Y. Kim et al., “Fecal hemoglobin concentration is useful for risk stratification of advanced colorectal neoplasia,” Digestive and Liver Disease, vol. 48, no. 6, pp. 667–672, 2016. View at Publisher · View at Google Scholar
  30. C. Alvarez-Urturi, M. Andreu, C. Hernandez et al., “Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening,” Digestive and Liver Disease, vol. 48, no. 5, pp. 542–551, 2016. View at Publisher · View at Google Scholar
  31. A. Kapidzic, M. P. van der Meulen, L. Hol et al., “Gender differences in fecal immunochemical test performance for early detection of colorectal neoplasia,” Clinical Gastroenterology and Hepatology, vol. 13, no. 8, pp. 1464.e4–1471.e4, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. L. G. M. Van Rossum, A. F. Van Rijn, R. J. F. Laheij et al., “Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme,” British Journal of Cancer, vol. 101, no. 8, pp. 1274–1281, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. Z. Levi, P. Rozen, R. Hazazi et al., “A quantitative immunochemical fecal occult blood test for colorectal neoplasia,” Annals of Internal Medicine, vol. 146, no. 4, pp. 244–255, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Rozen, D. Comaneshter, Z. Levi et al., “Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use,” Cancer, vol. 116, no. 9, pp. 2115–2125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. T. Van Turenhout, F. A. Oort, R. W. Van Der Hulst et al., “Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?” BMC Gastroenterology, vol. 14, article 217, 2014. View at Publisher · View at Google Scholar
  36. T. R. De Wijkerslooth, E. M. Stoop, P. M. Bossuyt et al., “Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia,” The American Journal of Gastroenterology, vol. 107, no. 10, pp. 1570–1578, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. J. M. Auge, M. Pellise, J. M. Escudero et al., “Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program,” Gastroenterology, vol. 147, no. 3, pp. 628.e1–636.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Canadian Partnership Against Cancer, Quality Determinants and Indicators for Measuring Colorectal Cancer Screening Program Performance in Canada, The Partnership, Toronto, Canada, 2012.
  39. D. A. Lieberman, D. K. Rex, S. J. Winawer, F. M. Giardiello, D. A. Johnson, and T. R. Levin, “Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the us multi-society task force on colorectal cancer,” Gastroenterology, vol. 143, no. 3, pp. 844–857, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. Y.-H. Lee, M. Hur, H. Kim et al., “Optimal cut-off concentration for a faecal immunochemical test for haemoglobin by Hemo Techt NS-Plus C15 system for the colorectal cancer screening,” Clinical Chemistry and Laboratory Medicine, vol. 53, no. 3, pp. e69–e71, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Randell, M. Kennell, A. Taher et al., “Evaluation of Hemo Techt NS-Plus system for use in a province-wide colorectal cancer screening program,” Clinical Biochemistry, vol. 46, no. 4-5, pp. 365–368, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. T.-H. Chiang, S.-L. Chuang, S. L.-S. Chen et al., “Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program,” Gastroenterology, vol. 147, no. 6, pp. 1317–1326, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. J. J. Telford, A. R. Levy, J. C. Sambrook, D. Zou, and R. A. Enns, “The cost-effectiveness of screening for colorectal cancer,” Canadian Medical Association Journal, vol. 182, no. 12, pp. 1307–1313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. S. J. Heitman, R. J. Hilsden, F. Au, S. Dowden, and B. J. Manns, “Colorectal cancer screening for average-risk north americans: an economic evaluation,” PLoS Medicine, vol. 7, no. 11, Article ID e1000370, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. A. J. Coldman, N. Phillips, J. Brisson et al., “Using the cancer risk management model to evaluate colorectal cancer screening options for Canada,” Current Oncology, vol. 22, no. 2, pp. e41–e50, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. J. A. Wilschut, L. Hol, E. Dekker et al., “Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening,” Gastroenterology, vol. 141, no. 5, pp. 1648–1655, 2011. View at Publisher · View at Google Scholar · View at Scopus